Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single?center study

Cander,Soner; Karkucak,Mutlu; Gul,Ozen Oz; Sag,Sebnem Ozemri; Yakut,Tahsin; Ersoy,Canan; Tuncel,Ercan; Erturk,Erdinc

doi:10.3892/br.2014.281

Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single?center study

Authors:
- Soner Cander
- Mutlu Karkucak
- Ozen Oz Gul
- Sebnem Ozemri Sag
- Tahsin Yakut
- Canan Ersoy
- Ercan Tuncel
- Erdinc Erturk
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, Uludag University Medical School, Gorukle, Bursa 16059, Turkey, Department of Medical Genetic, Uludag University Medical School, Gorukle, Bursa 16059, Turkey
Published online on: May 19, 2014 https://doi.org/10.3892/br.2014.281
Pages: 589-595

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pituitary tumors usually originate as benign sporadic adenomas and develop into invasive and aggressive tumors such as prolactinomas, which are common functioning pituitary adenomas. The aim of the present study was to examine the association between the tumor behavior in prolactinomas and the p16(CDKN2A) gene polymorphism occurring at the 3'?untranslated region of exon 3 (C540G). A total of 104 patients with prolactinoma were included and assigned to two groups based on invasive vs. non?invasive tumor behavior. Ki67 indices were recorded according to histopathology results. Genotypic analysis of the p16(CDKN2A) C540G polymorphism was carried out using a modified polymerase chain reaction?restriction fragment length polymorphism assay. The corresponding frequencies for CC, CG and GG genotypes in non?invasive vs. invasive tumors were 61.5, 30.8, 7.7 and 64.1, 28.2, 7.7%, respectively (not significant). The observed CG genotype frequency was higher compared with previous studies. In addition, the patients with giant adenomas or a high Ki67 index had a higher frequency of the CG genotype as compared with the other subgroups, although the differences were not significant (46.2 and 42.9%, respectively). In conclusion, a higher frequency of the C540G CG genotype of the CDKN2A gene was found among patients with prolactinoma in comparison with previous studies. These frequencies were also higher in the subgroups with elevated Ki67 or giant adenomas. Further studies are required to improve the definition of the role of the CG genotype in the development and progression of tumors in prolactinomas.

View Figures

View References

1	Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab. 91:3316–3323. 2006. View Article : Google Scholar : PubMed/NCBI
2	Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A and Klibanski A: Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest. 86:336–340. 1990. View Article : Google Scholar : PubMed/NCBI
3	Shimon I and Melmed S: Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab. 82:1675–1681. 1997.PubMed/NCBI
4	Landis CA, Masters SB, Spada A, Pace AM, Bourne HR and Vallar L: GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 340:692–696. 1989. View Article : Google Scholar : PubMed/NCBI
5	Shapiro GI: Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 24:1770–1783. 2006. View Article : Google Scholar : PubMed/NCBI
6	Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
7	Ogino A, Yoshino A, Katayama Y, Watanabe T, et al: The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol. 64:398–403. 2005.PubMed/NCBI
8	Fombonne J, Devouassoux-Shisheboran M, Bouvier R, Droz JP, Benahmed M and Krantic S: Analysis of p16INK4A gene promoter in male germ-cell tumors: identification of a new point mutation. Cancer Detect Prev. 29:1–7. 2005. View Article : Google Scholar : PubMed/NCBI
9	Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW and Lui WY: Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan. Oncol Rep. 15:507–511. 2006.PubMed/NCBI
10	Abbaszadegan MR, Raziee HR, Ghafarzadegan K, Shakeri MT, Afsharnezhad S and Ghavamnasiry MR: Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer. 36:47–54. 2005. View Article : Google Scholar : PubMed/NCBI
11	Ono Y, Ueki K, Joseph JT and Louis DN: Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. Acta Neuropathol. 91:221–225. 1996. View Article : Google Scholar : PubMed/NCBI
12	Zhang SJ, Endo S, Ichikawa T, Washiyama K and Kumanishi T: Frequent deletion and 5′ CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res. 58:1231–1237. 1998.
13	Simpson DJ, Bicknell JE, McNicol AM, Clayton RN and Farrell WE: Hypermethylation of the p16/CDKN2A/MTS1 gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer. 24:328–336. 1999. View Article : Google Scholar : PubMed/NCBI
14	Seemann N, Kuhn D, Wrocklage C, et al: CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol. 193:491–497. 2001. View Article : Google Scholar : PubMed/NCBI
15	Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS and Clayton RN: Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res. 57:2703–2709. 1997.PubMed/NCBI
16	Yoshimoto K, Tanaka C, Yamada S, et al: Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary adenomas. Eur J Endocrinol. 136:74–80. 1997. View Article : Google Scholar : PubMed/NCBI
17	Abd El-Moneim HM and Abd El-Rehim D: Immunohistochemical and molecular study of p16INK4A expression in pituitary adenoma. J Egypt Natl Canc Inst. 21:351–360. 2009.PubMed/NCBI
18	Sauroja I, Smeds J, Vlaykova T, Kumar R, et al: Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer. 28:404–414. 2000. View Article : Google Scholar : PubMed/NCBI
19	McCloud JM, Sivakumar R, Greenhough A, et al: p16^INK4apolymorphism: associations with tumour progression in patients with sporadic colorectal cancer. Int J Oncol. 25:1447–1452. 2004.
20	Yan L, Na W, Shan K, Xiao-Wei M, Wei G and Shu-Cheng C: p16(CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. Int J Gynecol Cancer. 18:30–35. 2008. View Article : Google Scholar : PubMed/NCBI
21	Simpson DJ, Fryer AA, Grossman AB, et al: Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis. 22:1801–1807. 2001. View Article : Google Scholar : PubMed/NCBI
22	Cottier JP, Destrieux C, Brunereau L, et al: Cavernous sinus ınvasion by pituitary adenoma: MR imaging. Radiology. 215:463–469. 2000.
23	Figarella-Branger D and Trouillas J: The new WHO classification of human pituitary tumors: comments. Acta Neuropathol. 111:71–72. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ono Y, Tamiya T, Ichikawa T, et al: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol. 55:1026–1031. 1996. View Article : Google Scholar : PubMed/NCBI
25	Biernat W, Tohma Y, Yonekawa Y, Kleihues P and Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 94:303–309. 1997. View Article : Google Scholar : PubMed/NCBI
26	Woloschak M, Yu A, Xiao J and Post KD: Frequent loss of the p16INK4a gene product in human pituitary tumors. Cancer Res. 56:2493–2496. 1996.PubMed/NCBI
27	Woloschak M, Yu A and Post KD: Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog. 19:221–224. 1997. View Article : Google Scholar : PubMed/NCBI
28	Jaffrain-Rea ML, Ferretti E, Toniato E, et al: p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clin Endocrinol (Oxf). 51:317–325. 1999. View Article : Google Scholar : PubMed/NCBI
29	Machiavelli G, Cotignola J, Danilowicz K, et al: Expression of p16(INK4A) gene in human pituitary tumours. Pituitary. 11:71–75. 2008. View Article : Google Scholar : PubMed/NCBI
30	Geddert H, Kiel S, Zotz RB, et al: Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol. 131:803–808. 2005. View Article : Google Scholar : PubMed/NCBI
31	Zheng Y, Shen H, Sturgis EM, et al: Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev. 11:640–645. 2002.
32	Thakur N, Hussain S, Nasare V, et al: Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep. 39:407–414. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chen J, Li D, Wei C, et al: Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res. 13:3100–3104. 2007. View Article : Google Scholar : PubMed/NCBI
34	Chen J, Li D, Killary AM, et al: Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol. 16:431–439. 2009. View Article : Google Scholar : PubMed/NCBI
35	Chansaenroj J, Theamboonlers A, Junyangdikul P, et al: Polymorphisms in TP53 (rs1042522), p16 (rs11515 and rs3088440) and NQO1 (rs1800566) genes in Thai cervical cancer patients with HPV 16 infection. Asian Pac J Cancer Prev. 14:341–346. 2013. View Article : Google Scholar : PubMed/NCBI
36	Tuna G, Küçükhüseyin O, Arıkan S, et al: Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression? DNA Cell Biol. 32:400–408. 2013.